Ampio Pharmaceuticals’ CEO Mike Martino Issues Letter to Stockholders

ENGLEWOOD, Colo., June 2, 2022 /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular…

Click here to view original post